Late-onset noninfectious pulmonary complications (LONIPCs) are life threatening for allogeneic hematopoietic SCT (allo-HSCT) recipients. However, the impact of LONIPCs on survival has not been properly evaluated and little is known about treatment efficacy. We retrospectively investigated 290 allo-HSCT recipients in our institute and reviewed the clinical aspects of 44 patients who had been diagnosed with LONIPCs. LONIPCs were significantly associated with higher rates of chronic GVHD (Po0001) and nonrelapse mortality (P ¼ 0.013), and lower rates of relapse (P ¼ 0.009). As a result of these effects, OS was significantly worse in those with LONIPCs (P ¼ 0.003). This result differs from a previous report. We then assessed short-term treatment response and final outcome. These results were defined by radiological findings, subjective symptoms, oxygen requirement and survival. Use of inhaled and systemic steroids did not affect either short-term response or final outcomes. However, administration of systemic corticosteroids earlier than at 21 days (median interval of time from onset of symptoms to systemic corticosteroids administration) was associated with a better outcome (P ¼ 0.054 for short-term response, and 0.016 for final outcome). Our study indicates that LONIPCs reduce OS, and early intervention with systemic corticosteroids may be effective.
Introduction
Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment option for a variety of hematological disorders. However, pulmonary complications develop in 25-60% of the recipients, and account for B50% of transplant-related deaths. [1] [2] [3] [4] [5] [6] Recently, the outcomes of infectious pulmonary complications improved as a result of advances in antimicrobial therapy, for example, against invasive fungal infection. 7 However, late-onset noninfectious pulmonary complications (LONIPCs) after allo-HSCT still remain potentially life threatening. 8, 9 After the first case report of fatal bronchiolitis in an allo-HSCT recipient with chronic GVHD (cGVHD) in 1982, 10 a series of LONIPCs were described in 1987 as smallairway disease in recipients of allo-HSCT. 11 In 1998, Palmas et al. 12 classified LONIPCs after allo-HSCT into five groups: bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP), diffuse alveolar damage, lymphocytic interstitial pneumonia and nonclassifiable pneumonia. According to this classification, BO was diagnosed based on the obstructive pattern in pulmonary function tests (PFTs) and the other LONIPCs on histological findings. 12 It is thus impractical to apply this classification to clinical settings because this criterion relies heavily on histology and lung specimens are not always available. These facts limited the standardization of Palmas's criteria and individual reports of LONIPCs use different classification criteria. 8, 9, 12 Recently, several studies have revealed many risk factors that are associated with the onset of LONIPCs, including cGVHD, 9, [12] [13] [14] [15] [16] [17] [18] [19] donor and recipient age, 13 baseline pulmonary function, 13 use of TBI, 20 and so on. There is a general agreement that cGVHD is the most strongly associated risk factor. 9, [12] [13] [14] [15] [16] [17] [18] [19] Although patients with LONIPCs have high nonrelapse mortality (NRM) rates, 9, 12 they experience low relapse rates of the underlying disease presumably because high concomitant rates of cGVHD exert a graft-vs-tumor effect. 9 Thus, it remains unknown whether the onset of LONIPCs has an impact on OS or relapse-free survival as a consequence of these contradictory factors. Only one study reported that survival of patients with and without LONIPCs was not significantly different. 9 Standard therapies for LONIPCs have not been established. Inhaled steroids and bronchodilators are supposed to be effective for BO. 21 High-dose corticosteroid therapy was suggested to be a valuable treatment option in pediatric patients with BO. 22 However, the role of systemic administration of corticosteroids for adults with LONIPCs has not been clarified.
To better understand the pathophysiology of LONIPCs, we investigated computed tomography (CT) images, pathological specimens and medical records of all adult patients who had received allo-HSCT for a hematological disorder in our institute and identified patients who had LONIPCs, as a result of which we examined the effect of LONIPCs on survival. Furthermore, we investigated diagnostic criteria, risk factors and treatment outcome of LONIPCs. Especially, we analyzed whether time to administration of systemic corticosteroids from appearance of symptoms affects outcomes, to explore the relevance of early intervention.
Patients and methods

Patient selection
We retrospectively studied 314 consecutive adult patients (age 16-67 years old, median 40 years old) with hematological disorders who underwent allo-HSCT at the University of Tokyo Hospital, Japan, between June 1995 and December 2007, of whom 290 patients were included in this study; 24 patients were excluded due to death within 60 days after allo-HSCT. Clinical information was obtained from detailed review of medical charts, institute database and computer ordering system.
Protocols for allo-HSCT
Myeloablative conditioning regimens included either TBIbased regimens or non-TBI-based regimens. TBI-based regimens mainly consisted of CY (60 mg/kg/day for 2 days) plus fractionated TBI (12 Gy), whereas non-TBI-based regimens included BU (1 mg/kg orally or 0.8 mg/kg i.v. every 6 h for 4 days) plus CY (60 mg/kg/day for 2 days). Patients were offered nonmyeloablative conditioning regimens when they were ineligible for myeloablative preparative regimens because of (1) age X56 years (n ¼ 28); (2) preexisting significant comorbidities (n ¼ 5, severe cardiac dysfunction (n ¼ 3), invasive pulmonary aspergillosis (n ¼ 1), interstitial pneumonia caused by granulocyte colony stimulating factor (n ¼ 1)); (3) a history of highdose HSCT (n ¼ 8; two patients were also over age); and (4) allo-HSCT for Hodgkin's lymphoma (n ¼ 1). Nonmyeloablative conditioning consisted of fludarabine-based regimens with or without low-dose TBI (4 Gy). Prophylaxis for GVHD was performed with calcineurin inhibitors (CsA or tacrolimus) with or without short-term MTX (sMTX) in most patients. In vivo T-cell depletion using alemtuzumab was performed in 26 patients for HLA 1 haplotypemismatched patients, concomitant with CsA and sMTX. 23 HLA matching for donor selection was based on serological typing for HLA-A and -B Ags, and molecular typing for HLA-DRB1 Ag. Disease morphology was determined according to the French-American-British classification. Standard risk diseases were defined as acute leukemia in first or second CR, CML in first or second chronic phase, chemosensitive lymphoma, myelodysplastic syndrome with refractory anemia or refractory anemia with ringed sideroblasts, and aplastic anemia. All other conditions were classified as high-risk diseases. Prophylaxis against bacterial infection was principally performed with quinolones, fungal infection with fluconazole or itraconazole, herpes simplex virus infection with acyclovir and Pneumocystis jiroveci infection with sulfamethoxazole/trimethoprim.
PFTs
Routine PFTs were performed before transplantation (except for four patients). After allo-HSCT, most patients with cGVHD received PFTs every 3-6 months. The restrictive pattern was assumed to have reduced the vital capacity (VC) to o80% of the expected values. The obstructive pattern was assumed to have a forced expiratory volume in 1 s (FEV1) of o70% of forced VC (FVC). When these two criteria are fulfilled concurrently, a diagnosis of mixed pattern was made.
Definition and classification of LONIPCs
A diagnosis of LONIPCs was made when a patient fulfilled all the following criteria: (1) respiratory symptoms developing after 60 days from allo-HSCT, (2) no evidence of infection detected despite extensive examinations, (3) at least one of the following abnormalities observed: (a) abnormal interstitial shadow on chest CT, (b) pathological diagnosis of interstitial pneumonia or BO, c) PFT revealing an obstructive or mixed pattern and a decline of FEV1 to o75% of the predicted value, or a decline of at least 20% FEV1 from baseline.
The CT images were reviewed by two expert chest radiologists and pathological specimens were reviewed by an expert pathologist. To exclude infection, standard culture and staining methods for bacterial, fungal and viral pathogens were used. Bronchoalveolar lavage was collected whenever possible, and subjected to bacterial and fungal culture, aspergillus galactomannan and multiplex PCR tests for herpes group viruses.
We then classified subtypes of LONIPCs. BO was defined according to the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease criteria. 24 Briefly, BO is diagnosed clinically when both the following criteria in addition to that of LONIPCs are met: (1) LONIPCs criteria 3 (c), and (2) evidence of air trapping or small-airway thickening or bronchiectasis on high-resolution chest CT (with inspiratory and expiratory cuts), residual volume X120% or pathological confirmation of constrictive bronchiolitis. 24, 25 LONIPCs other than BO were classified based on either radiological or pathological findings, according to the American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. 26 CT findings at the onset of respiratory symptoms, after 2-8 weeks from the start of treatment and at the last follow-up were reviewed and evaluated by two radiologists. Patients having air space consolidation (especially in the lower lobes), peribronchial small nodules and multiple solid nodules are classified as cryptogenic organizing pneumonia, whereas those with bilaterally symmetric, peripheral ground glass shadowing are classified as nonspecific interstitial pneumonia. No patient conformed radiologically to idiopathic pulmonary fibrosis, acute interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease or lymphocytic interstitial pneumonia. Lung histology of transbronchial lung biopsy, necropsy and autopsy were reviewed by a pathologist. Pathological classification was ascribed to Palmas et al.
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Evaluation of treatment outcomes Short-term response was defined as those who received either or both inhalant or systemic corticosteroid therapy, and start of therapy was defined as the administration of either form, whichever came first. Short-term response was assumed to be responsive when patients fulfilled at least two out of the following three criteria in 2-4 weeks after the start of therapy: (1) at least 50% decrease of supplemental oxygen requirement or ventilator weaning; (2) improvement in subjective respiratory symptoms; and (3) improvement in radiological findings. The same criteria were applied at the last follow-up and defined as the final outcome. Those who received neither inhaled nor systemic corticosteroid were included. Dead patients were considered nonresponders.
Statistical methods
Duration of follow-up was the time from transplantation to the last assessment for survivors. Variables regarding patients, underlying diseases and transplantation procedures were compared between patients with and without LONIPCs using the Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables. A multivariate analysis using a logistic regression model was conducted including the following factors as potentially significant: sex, age (o55 vs X55 years old), disease risk, number of previous HSCT, graft source (peripheral blood vs others), HLA compatibility (matched related donor vs matched unrelated donor vs mismatched donor), donor-recipient sex mismatch, intensity of conditioning (myeloablative vs reduced intensity), GVHD prophylaxis (with alemtuzumab vs without) and existence of acute and chronic GVHD. Probabilities of OS were calculated with the Kaplan-Meier method, treating the onset of LONIPCs as a time-dependent covariate, and were compared using the log-rank test. In the time-dependent analysis, a covariate indicates whether a patient has LONIPCs before time t. Note that this covariate is initially zero in all cases and changes to 1 at the time when the patient develops LONIPCs. 27 For analysis of OS, death from any cause was considered an event, and data on patients who were alive at the last follow-up were censored. Probabilities of NRM, relapse, acute and chronic GVHD were calculated with the cumulative incidence function method. 28 For NRM, relapse was the competing event; for relapse, NRM was the competing event; and for GVHD, death without GVHD was the competing event. Patients who were alive without an event were censored at last follow-up. Comparisons of short-term response and final outcome between two groups were performed with the Fisher's exact test. Results of PFTs were compared with one-sided t-tests. All P-values except for PFTs ( Figure 3) were two-sided, with a type I error rate fixed at 0.05. Statistical analyses were performed with R 2.6.2 software (The R Foundation for Statistical Computing, 2007).
Ethical problems
We obtained written informed consent from allo-HSCT recipients to use their clinical data. This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Tokyo University Hospital.
Results
Patient characteristics
Of the 290 patients who survived more than 60 days after allo-HSCT, 44 (15.2%) developed LONIPCs. Comparisons of patient characteristics between patients with and without LONIPCs are shown in Table 1 . Male sex (P ¼ 0.041) and donor-recipient sex mismatch (P ¼ 0.021) were associated with a higher incidence of LONIPCs. Multivariate analysis revealed that male sex (P ¼ 0.006), donor-recipient sex mismatch (P ¼ 0.001) and existence of cGVHD (Po0.001) were independent risk factor of LONIPCs.
Clinical, radiological and pathological presentation of LONIPCs Before allo-HSCT, only five patients had shown abnormal PFTs (hemoglobin-corrected diffusing capacity of carbon monoxide o80% in four patients, obstructive pattern in one patient) and three patients had been smokers. Of 44 patients who were diagnosed with LONIPCs, 21 were classified as BO, 28 as LONIPCs other than BO and 5 patients fulfilled the criteria of both BO and other LONIPCs. The median time to diagnosis of LONIPCs was 292 days after allo-HSCT (range 61-2169 days). In all, 19 patients complained of dry cough as an initial symptom, whereas 7 patients complained of productive cough, and 27 patients complained of dyspnea. Only six patients had fever and four had sputum. Out of 21 patients diagnosed with BO, 12 had CT findings compatible with BO, and the other nine were shown to have increased residual volume in PFT. 24 Of the 28 patients diagnosed with LONIPCs other than BO, a pathological diagnosis was available in 10 patients (TBLB for three patients, autopsy for six patients and both TBLB and autopsy for one patient, four patients diagnosed with BOOP, three with diffuse alveolar damage and three with nonspecific alveolitis or pneumonia). Bronchoalveolar lavage was collected to exclude infectious lung complications in 18 patients. Nine patients required ventilator support, and only one was successfully extubated. Altogether, 32 patients were discharged at least once Outcome and treatment of LONIPCs K Ueda et al after the onset of LONIPCs, and home oxygen therapy was started in 14 patients. Eight patients developed a pneumothorax and/or mediastinal emphysema during the course of disease.
Survival and relationship between LONIPCs and GVHD, relapse and NRM The OS of patients with LONIPCs was significantly worse compared with those without LONIPCs when the onset of LONIPCs was treated as a time-dependent covariant as shown in Figure 1 (P ¼ 0.003). Although the incidence of grades II-IV acute GVHD was not different in LONIPCs ( þ ) and LONIPCs (À) groups (P ¼ 0.942, Figure 2a) , extensive cGVHD was significantly more common in the LONIPCs ( þ ) group (Po0.001, Figure 2b) . A cumulative incidence of relapse was lower in LONIPCs ( þ ) group (P ¼ 0.009, Figure 2c) . However, NRM rates were higher in the LONIPCs ( þ ) arm (P ¼ 0.013, Figure 2d ).
Treatment and outcomes
We administered inhaled steroid and a b-stimulator to 12 patients, 9 of whom had BO. As shown in Table 2a , administration of inhalant steroid did not affect outcomes. Seventeen patients received reinitiation or dose escalation of calcineurin inhibitors. Systemic corticosteroids were administered to 31 patients who received high-dose methylprednisolone; 1000 mg for 3 days, whereas others received 0.5-1.0 mg prednisolone orally or i.v.), and this also failed to influence outcome as shown in Table 2a . Next, we divided the patients into three groups: those who received systemic corticosteroids before 21 days (median of all corticosteroid recipients) from appearance of respiratory symptoms (early steroid); those who received them after 22 days from the onset (late steroid); and those who did not receive (steroid-). The early steroid group had a trend of showing a better short-term response and had significantly better final outcomes compared with the late steroid and the steroid-groups, as shown in Table 2b (P ¼ 0.054 for short-term response, P ¼ 0.016 for final outcome, respectively). When we evaluated early response and final outcome of BO and LONIPCs other than BO separately, only final outcome of BO was significantly improved by early administration of corticosteroids (P ¼ 0.546 for early response of BO, P ¼ 0.041 for final outcome of BO, P ¼ 0.411 for early response of LONIPCs other than BO, P ¼ 0.228 for final outcome of LONIPCs other than BO). As for patients who received high-dose methylprednisolone, any advantage of early steroid was not statistically significant (P ¼ 0.282). Next, we compared FEV1/FEV1 predicted in the three groups, early steroid, late steroid and steroid-. As shown in Figure 3 , FEV1/ FEV1-predicted values in the early steroid group at last follow-up was significantly higher than those of the steroidgroup (P ¼ 0.039) or the late steroid group (P ¼ 0.033).
At last follow-up, 20 patients out of 44 had died and the median from onset of LONIPCs to death of these 20 patients was 278 days (range: 31-2315). The cause of death was respiratory failure in 17 patients, and respiratory infection was involved in the cause of death in only two patients.
Discussion
Previous reports of LONIPCs included patients with respiratory syndromes that developed after the first 2 or 3 months from allo-HSCT without any evidence of infec- Abbreviation: LONIPCs ¼ late-onset noninfectious pulmonary complications. P-value indicates the statistical significance of difference between steroid within 21 days (+) and steroid within 21 days (À) groups using Fisher's exact test.
Outcome and treatment of LONIPCs K Ueda et al tion. 8, 9, 12 The time after HSCT for patients with noninfectious pulmonary complications to be diagnosed with LONIPCs differed from study to study. 9, 12 Although some studies set the threshold at 90 days, 9 we set it at 60 days based on the observation that, in our cohort, five patients developed respiratory symptoms without any evidence of infection between 60 and 90 days after allo-HSCT. Because their clinical courses were typical for LONIPCs in that they did not fulfill criteria of other lung complications and responded to corticosteroids, we considered it reasonable to include them in the study. On the other hand, although four patients who received allo-HSCT in our institution developed respiratory symptoms within 60 days (days 19, 32, 40 and 48) after allo-HSCT, we excluded them from our study because we had difficulty in distinguishing them from idiopathic pneumonia syndrome 29 or engraftment syndrome. 30 In our study, those patients whose FEV1 decreased at least 20% from the baseline were diagnosed with BO even if FEV1/FVC ratio was over 0.7. This condition was not included in the previous criteria for BO.
9,12 However, we used this criterion because it is recommended to be one of the diagnostic criteria for BO 25 in the disease category derived from obliterative bronchiolitis after lung transplantation as BO syndrome (BOS). 31, 32 The criteria of BOS are based on the idea that recognition of small air way obstruction is more sensitive than that of decline of FEV1/FVC. 31 Otherwise, reduction of FVC would mask obstructive change, thus we considered that these criteria are reasonable. Four patients were actually diagnosed according to these criteria.
Because the classification of LONIPCs other than BO still remains unsettled, we reviewed previous reports and classified them by both radiological and pathological findings. Although Palmas's classification has been widely used for LONIPCs, 12 we found it impractical to apply this classification because this system requires lung specimens, which are not always available. We therefore used radiological criteria of interstitial pneumonia 26 for cases without lung pathology, and we applied both radiological and pathological classifications to the cases with lung pathology. In support of this is the recommendation that histopathological, clinical and radiological classification should be considered comprehensively in the field of idiopathic pneumonia or small-airway diseases. 26, 33, 34 In these previous reports, the authors claimed that initial classification of interstitial pneumonia should be made with available information such as CT or clinical presentation, and the initial diagnosis should be revised in the light of new information such as histology. They also mentioned that when histology is incompatible with clinical and radiological appearances, pathological diagnosis should not be finalized. 33, 34 In this study, male patients and patients with donorrecipient sex mismatch were associated with a higher incidence of LONIPCs. Furthermore, a cumulative incidence of cGVHD and NRM was more frequent in patients with LONIPCs than those without. These findings are compatible with previous reports. 9, 12, [17] [18] [19] On the other hand, reduced-intensity conditioning 35 and use of alemtuzumab did not reduce LONIPCs in our study, which was not compatible with previous reports.
Relapse of hematological disorders was less frequent in patients with LONIPCs, as previously reported. 9 This supports the hypothesis that the presence of LONIPCs is associated with a strong graft-versus-tumor effect. On the other hand, LONIPCs significantly increased NRM rates; 20 patients out of 44 with LONIPCs had died at last followup, including 11 who died within 1 year after onset of LONIPCs. This negative effect of LONIPCs on mortality was strong enough to outweigh the favorable impact on a decrease in relapse rate, which clearly worsens OS in cohorts with LONIPCs. The OS of patients with or without LONIPCs has not been reported to be significantly different, 9 and we suppose that employment of timedependent analysis or not might account for the different outcome. It is of note that time-dependent analysis is required for validating the effect of LONIPCs on survival because onset of LONIPCs cannot be predicted on day 0 of HSCT. 27 Routine PFTs are recommended before transplantation, and are also recommended after transplantation for patients with cGVHD every 3-6 months. Pretransplantation abnormalities in PFTs are reported to predict poor pulmonary outcomes in survivors after allo-HSCT. 36, 37 In our cohort, however, only two patients who developed BO had abnormal PFTs before transplantation. Therefore, we cannot evaluate the usefulness of pretransplant PFTs. Although abnormal post-transplant PFTs are also reported to predict LONIPCs, 38 only four patients had abnormal PFTs between allo-HSCT and onset of BO in our cohort. These results indicate that it is difficult to detect airway obstruction before the appearance of respiratory symptoms unless PFTs are more frequent. Telemetric monitoring of PFTs is one of the effective ways of detecting BO earlier, 39 which may be considered for outpatients with cGVHD who are at high risk of LONIPCs.
As for treatment of LONIPCs, no promising therapy has been reported. Although inhaled steroids and bronchodilators are reported to improve respiratory function of Late steroid means that corticosteroids are administered systemically after 22 days from onset of symptoms and early steroid means that corticosteroids are administered before 21 days from onset. FEV1/FEV1 predicted at last follow-up was significantly high in the early steroid group compared with the other two groups (*P ¼ 0.033, **P ¼ 0.039). FEV1, forced expiratory volume in 1 s; HSCT, hematopoietic SCT; LONIPCs, late-onset noninfectious pulmonary complications.
patients with BO, 21, 40 use of these agents did not affect outcome in our cohort. Although 0.5-1.0 mg/kg corticosteroids are recommended to treat BOOP [41] [42] [43] and highdose corticosteroids are reported to be effective for pediatric cases with BO, 22 the effect of corticosteroids for adult patients with LONIPCs including BO is still unknown. Using the composite evaluation system of outcomes that includes symptoms, supplemental oxygen necessity and radiological change, we found that early administration of systemic corticosteroids leads to good outcomes in patients with LONIPCs. As for patients with BO, two out of three in the early steroid group has improved, whereas only two out of seven patients in the late steroid group improved, Although seven patients in the early steroid group had already received calcineurin inhibitors at the start of corticosteroids, five patients responded to corticosteroids. We cannot evaluate whether high-dose methylprednisolone is effective for patients with LONIPCs in this study because we tended to administer high-dose methylprednisolone for patients with severe and progressive diffuse alveolar damage or cryptogenic organizing pneumonia/BOOP, and for these patients, advantage of early steroid was not significant, as stated above.
Early steroid administration was significantly associated with a better final outcome of LONIPCs. It is difficult to associate this result with PFTs because analysis of the PFT profile shows that systemic steroid therapy serves only to stop further deterioration of PFTs, and the difference in PFT results in final assessment between early and late steroid group could be attributed to the differences in these at the time of LONIPCs diagnosis ( Figure 3) . This underscores the significance of diagnosing LONIPCs before PFTs deteriorate. Although PFT recovery after steroid therapy was limited in early and late steroid groups as a whole, detailed analysis of individual patients suggests that PFT recovery is associated with a better outcome (three out of five patients who had improved outcome according to our criteria had PFT recovery, although none of the 19 nonimproved patients had) and we consider this represents one aspect of lung function. These results suggest that early administration of corticosteroids prevents pulmonary fibrosis and leads to better outcomes. This hypothesis is supported by the fact that delayed administration of corticosteroids increases relapse of cryptogenic organizing pneumonia, 42 and early administration of corticosteroids leads to a good outcome in preterm infants by inhibiting fibrogenic mediators. 44 We presume that any positive effect of early administration of corticosteroids could be adapted to other specific cytokine inhibitors such as etanercept. Further study is required on this point.
In conclusion, this study demonstrates that patients developing LONIPCs have a poor prognosis despite a lower incidence of relapse. Furthermore, detection of LONIPCs before the appearance of respiratory symptoms is difficult unless PFTs are performed more frequently. Once patients have developed LONIPCs, early administration of corticosteroids might be effective and lead to a better outcome. Our recommendations for patients with respiratory symptoms are therefore as follows: (1) Exclusion of infection should be done as soon as possible, even for outpatients. (2) After an infectious etiology has been excluded, 0.5-1.0 mg/kg corticosteroids should be administered systemically as soon as possible.
This study has several limitations. This study was a retrospective, single-institute study including various patients' backgrounds. In addition, the relatively small number of patients made it difficult to conduct multivariate analyses. Although prospective study is difficult in treating rare complications after HSCT, multicenter, large-scale studies are necessary to confirm our findings.
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